Improved Production of Influenza Virus, Including H1N1, for Vaccine Manufacture

Wisconsin Alumni Research Foundation (University of Wisconsin)
posted on 07/13/2010

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a method and composition for improving production of vaccines against influenza viruses, including H1N1.

Suggested Uses

Production of H1N1 vaccine
Production of vaccines against other viruses
Viral mutagenesis studies
Identification of other HA mutations that alter growth of influenza virus

Advantages

Significantly improves growth of influenza virus in cultured cells, including Vero cells
Enhances manufacturing of influenza vaccines, including vaccines against the H1N1 strain
Does not require helper virus

Innovation Details

Detailed Description

The H1N1 influenza virus, known as the “swine flu,” has been declared a pandemic. While this virus is less virulent than many circulating strains of flu virus, it has become the subject of significant public health efforts, including international stockpiling of vaccine. However, this virus is less amenable to high titer production than many of the more common influenza viruses, making vaccine manufacture challenging.

UW-Madison researchers have identified a single point mutation in the haemagglutinin (HA) gene of the H1N1 virus that enhances viral titer. Introducing the mutation into vaccine seed viruses could lead to higher titer production of the viruses, improving vaccine manufacture.

File Number: P100078US02

IP Protection

License Online

This innovation currently is not available for online licensing. Please contact Emily Bauer at Wisconsin Alumni Research Foundation (University of Wisconsin) for more information.

request more info